The Grey-Market Peptide Customer Is Now a Target for US Pharmacies The FDA hasn’t finalised its proposed peptide-compounding policy, but one US healthcare company is already planning to target customers who've been buying peptides through the grey market. On 16 October, DataMeds AI (NASDAQ: MEDS) announced plans to expand its Corexa Health operations into the emerging market for pharmacy-compounded peptides. Buried in the announcement was a particularly interesting statement: “DataMEDS intends to initially focus its peptides marketing towards patients who have historically obtained peptides through the grey market.” That’s a fairly direct acknowledgement of a customer base that pharmaceutical and healthcare businesses have often preferred to distance themselves from. Corexa Pharmacy is already an established Section 503A compounding pharmacy. The company intends to begin dispensing eligible peptides if the FDA’s proposed interim access policy takes effect. It also has much of the infrastructure in place. Its distribution division operates a 40,000-square-foot warehouse in Florida, reports licensing across all 50 US states and has access to a network of more than 6,500 independent pharmacies. Its technology division plans to connect doctors, patients and pharmacies through the Health Lives Here app, handling prescription referrals and helping patients access compounded treatments. DataMeds expects the market to be predominantly cash-pay, which it sees as an advantage because it reduces reliance on insurance reimbursement. The company is already reviewing potential peptide API suppliers and expects to arrange sourcing contracts in the coming weeks. The FDA policy remains a proposal, with the final list of eligible peptides and conditions for compounding still to be confirmed. But will grey-market customers actually move? This is where DataMeds’ strategy becomes interesting. Many established peptide buyers use the grey market precisely because of price and access. Some purchase directly from Chinese suppliers, arrange independent laboratory testing and still pay considerably less than they would through a typical US pharmacy. DataMeds wants to introduce prescriptions, licensed compounding, US distribution and a telehealth platform. All of those services come with costs. There will undoubtedly be customers willing to pay more for regulated sourcing, medical supervision and convenience. But converting price-conscious grey-market buyers into cash-paying pharmacy customers could prove difficult. The company has identified an existing customer base, but identifying those customers and persuading them to change how they buy are two very different things. The irony is that DataMeds sees grey-market buyers as a commercial opportunity, while the prices that attracted many of those buyers to the grey market may be exactly what keeps them there. The FDA is still working out the rules. DataMeds is already working out how to get the customers. Source: DataMeds AI / Corexa Health announcement, 16 October 2026.